痛みを伴う処置を受ける乳児の痛みを管理するオピオイド 要点 - 強力なエビデンスがないため、痛みを伴う処置を受ける乳児の痛みを管理するためのオピオイドの利点とリスクは不明である。 - プラセボ（薬を含まないが、試験中の薬と同じように見える「ダミー」治療、偽治療）と比較すると、オピオイドは、処置中に特定の尺度で評価される痛みを軽減するかもしれないが、処置の1～2時間後に他の尺度で評価される痛みには違いがないかもしれない。 - 他の疼痛スコアや異なる時点における疼痛評価、徐脈（心拍数の低下）や低血圧のエピソードに対するオピオイドの影響については、非常に不確かである。オピオイドは呼吸停止のエピソードを増加させる可能性がある。 なぜオピオイドは、乳児の処置中の痛みを管理するために投与されるのか？ 乳児（特に生後4週間）は、入院中に痛みを伴う処置を受けることが多い。成人と同様、これらの処置中も、継続した疼痛管理とコントロールが必要である。オピオイドは、体内の細胞にあるオピオイド受容体と相互作用することで効果を発揮する、痛みを和らげる薬の幅広いグループであり、乳幼児によく使用される。 知りたかったこと 痛みを伴う処置を受ける乳児に、オピオイドが以下の治療と比較して、どのような影響を及ぼすかを調べたかった： - 無治療またはプラセボ； - 薬物以外の治療（甘い溶液など）； - 他の薬； - 異...

前立腺肥大症に対する ノコギリヤシ（Serenoa repens） レビューの論点 Serenoa repens（ノコギリヤシ）単独あるいは他の植物治療剤との併用は、前立腺肥大症の男性の症状を改善するか？ 背景 前立腺が肥大すると、日中や夜間に頻繁に尿意をもよおしたり、尿の出が悪くなったり、残尿感があるなど、煩わしい尿路症状が現れることがあるかもしれない。一般的な薬剤を用いた介入のほかに、植物やハーブの使用（植物療法）は一般的であり、多くの西洋諸国で徐々に増えてきている。アメリカノコギリヤシ（矮性椰子）（American saw palmetto、dwarf palm plant）、Serenoa repens（ノコギリヤシ）（植物学名Sabal serrulatumとしても知られている）の抽出物（エキス）は、この症状の治療に利用されているいくつかの植物治療薬のひとつである。 研究の特性 ノコギリヤシ単独または他のハーブ製品との併用とプラセボ（実際には治療を受けていないが、治療を受けたと参加者に思い込ませる方法）を比較した男性4,656例を対象とした27件の研究を同定した。ほとんどの研究は、中程度の症状を有する50歳以上の男性を対象としていた。10件の研究は製薬企業から資金提供を受け、2件の研究は政府から資金提供を受けていた。残りの研究は資金供給元に関する報告がなかった。 主要な...

低グリセミック・インデックス（GI）食または低グリセミック負荷（GL）食は、過体重または肥満の減量に役立つか。 主要な結果 低グリセミック・インデックス（glycaemic index：GI）食または低グリセミック負荷（glycaemic load ：GL）食は、高GI食または高GL食など他の食事と比べて、おそらく体重にほとんどまたは全く差を生じない。 これらの食事が人々の生活の質（Quality of Life：QOL）、副作用、死亡に及ぼす影響については非常に不確かである。 低GI食または低GL食とはどんなものか？ 低GI食または低GL食は、血糖値の上昇を穏やかにしたり、遅らせたりする食品で構成される。そのため、体内でのインスリン分泌が少なくなり、体重減少につながるかもしれない。 わかったこと 過体重または肥満の人々におけるこれらの食事の効果を評価したいと考えた。体重、QOL、副作用、死亡への影響を検証した。 実施したこと 過体重または肥満の成人におけるこれらの食事の効果を、高血糖指数食または高血糖負荷食（血糖値が急上昇するような食事）などの他の食事と比較した研究を検索した。これらの研究は少なくとも8週間の追跡調査を条件とした。 わかったこと 1,210例（参加者の4.1％は小児、1.9％は65歳以上の成人）を対象とした10件の研究を組み入れた。これらの研究の半数は米国で実施...

Global leaders in evidence-based healthcare highlight the urgent need to advance global health equity

Cochrane has partnered with JBI, Campbell Collaboration, GIN, the Institute for Evidence-Based Healthcare, the Centre for Evidence-based Health Care and NICE to launch the 2023 campaign for World Evidence-Based Healthcare (EBHC) Day, called ‘Evidence and Global Health Equity’.  

World EBHC Day is held on 20 October each year. It is a global initiative that raises awareness of the need for better evidence to inform healthcare policy, practice and decision-making in order to improve health outcomes globally. It is an opportunity to participate in debate about global trends and challenges and celebrate the impact of individuals and organisations worldwide, recognising the work of dedicated researchers, policymakers and health professionals in improving health outcomes. 

The 2023 campaign aims to examine how the global evidence community can foster and embed equity within and across evidence ecosystems to advance global health equity and inspire a collective drive among individuals and organisations to challenge the status quo and embrace a new paradigm of evidence generation and utilisation that propels progress towards the Sustainable Development Goals.

“In 2023 we reached the mid-way point for the 2030 United Nations Sustainable Development Goals and a global commitment to ‘leave no one behind’, says World Evidence-Based Healthcare Day Chair, Bianca Pilla. "However, the global crises of humanitarian disasters, climate change and health pandemics are all impeding progress and exacerbating global health inequities, highlighting the urgency to strengthen local and global evidence ecosystems to address societal challenges."

Evidence is a prerequisite for achieving global health equity. Equitable health policies, systems and services are all dependent on functioning evidence ecosystems: the generation and application of evidence, whether this is by the public, health workers, researchers or policymakers.

"Global health equity rests on the foundation of robust evidence ecosystems," says Catherine Spencer, Cochrane CEO. "As a trusted leader in synthesizing health evidence for over 30 years, Cochrane is fully dedicated to promoting equity. We are excited to collaborate with the other World Evidence-Based Healthcare Day partners to emphasize that the development of equitable health policies, systems, and services hinges upon the effective generation and application of evidence by the public, health workers, researchers, and policymakers. Together, we can drive meaningful change and foster a future of inclusive healthcare."

In 2023 the organising partners have invited Health Information for All (HIFA), E-Base Africa, International Initiative for Impact Evaluation (3ie), The George Institute for Global Health and University of Global Health Equity as campaign partners. Campaign partners collaborate with the organising partners of World Evidence-Based Healthcare Day to contribute to developing and strengthening the campaign, ‘Evidence and Global Health Equity’, with unique expertise, knowledge and resources.

The 2023 campaign is a call to action to take concrete steps towards equity-centred evidence-informed decision making, drawing attention to the need to enhance collaboration, information sharing and networking to increase access to research evidence, and to move towards integrated systems that prioritise equity, inclusivity and multisectoral participation of all actors.  

Many in the Cochrane community have submitted blogs, vlogs, and events for World Evidence-Based Healthcare Day to help share experiences and collective wisdom on fostering equity-centred evidence-informed decision-making and strengthening evidence ecosystems - check them out!

•  Visit the World EBH Day website

 

Wednesday, October 11, 2023 Category: The difference we make

早産児の経口哺乳に対する口腔刺激の効果 レビューの論点 妊娠37週より前に生まれた早産児に、指による刺激を用いた口腔刺激介入を行う： 完全経口哺乳を達成するまでの期間（日数）の短縮につながるか？ 新生児集中治療室（Neonatal Intensive Care：NICU）で過ごす期間（日数）の短縮につながるか？ 入院期間（日数）の短縮につながるか？ 栄養チューブ（経静脈栄養）により栄養補給される期間（日数）の短縮につながるか？ 背景 これは2016年のレビューのアップデート版である。多くの早産児は、経口（吸啜）哺乳の確立が遅く、最初は栄養チューブや経静脈（非経口）栄養により栄養補給される。経口哺乳能力の発達には、吸啜、嚥下、呼吸の綿密な協調を必要とする。早産児における経口哺乳の確立は困難な場合がある。その理由として、入院期間が長いこと、呼吸困難および早産に関連するその他の医学的症状を呈することが挙げられる。人工呼吸、および口や鼻からの頻回の分泌物吸引といった不快な処置は、経口哺乳能力に悪影響を及ぼす可能性がある。経管栄養から経口哺乳への移行に関する国際的なガイドラインは、内容のばらつきが大きい。医療従事者は、早産時の吸啜・哺乳能力を向上させるためにさまざまな介入を用いており、経管栄養から経口哺乳への移行期間の短縮、入院期間の短縮、乳児の吸啜能力の向上につながることが複数の研究で報...

固定式装置を用いた歯科矯正治療中の患者において、歯の移動を促進させるための補助的な非外科的治療法 論点 矯正力による歯の移動（OTM）を促進すると言われている非外科的処置の追加により、歯科矯正治療全体の治療期間が短縮するか？ 背景 若年者や成人の歯並びや噛み合わせに問題がある場合、歯の位置を矯正するための歯科矯正治療が世界的に行われている。使用される矯正装置の種類はさまざまであり、自分で取り外しのできない固定式矯正装置（ワイヤーを固定するためのブラケットを歯に接着した上で、矯正用ワイヤーを連結して用いるものなど）や自分で取り外しが可能な可撤式矯正装置（透明な樹脂で作製されたマウスピースタイプのものなど）がある。歯や噛み合わせの状態によって、治療期間は数か月から数年に及ぶことがあるが、全ての歯を対象とした歯科矯正治療のほとんどでは、通常20か月程度を要する。歯科矯正治療は、笑顔を改善し、患者に良い影響を与えることは知られているものの、う蝕、あるいは歯根吸収（OIIRR）の発生などのリスクも伴う。OTMを促進させることで、治療期間を短縮し、時々起こり得る有害事象を軽減できる可能性がある。そのために、外科的治療や非外科的治療を含むいくつかの方法が提案されている。本レビューでは、OTMを促進させるための非外科的治療に関するエビデンスについて評価を行った。 今回、コクラン・オーラルヘルスの...

Monday, June 19, 2023

Jheng-Yan Wu shares how Cochrane has impacted his professional development and his clinical practice. 

A dietitian from Taiwan, Jheng-Yan Wu, has made waves in the global medical community by proudly displaying a permanent Cochrane logo tattoo on his forearm. Wu's decision to immortalize the iconic symbol in a tattoo signifies his unwavering dedication to evidence-based healthcare and the application of systematic reviews and meta-analysis in his clinical practice.

Wu's journey with Cochrane began in 2018 when he was first introduced to evidence-based medicine. Captivated by Cochrane's emphasis on global collaboration and its mission to enhance healthcare, Wu worked with Cochrane Taiwan, volunteering his time to translate six plain language summaries from English to Traditional Chinese. These translations aim to improve accessibility and knowledge dissemination, ensuring that evidence-based resources reach a global audience.

The year 2022 marked a significant turning point for Wu, as he took on the challenge of learning about the methodology behind writing systematic reviews and meta-analyses. Immersing himself in the wealth of techniques outlined in the Cochrane Handbook of Systematic Reviews of Interventions and other resources on Cochrane Training, Wu deepened his understanding of evidence synthesis and further fueled his passion for incorporating rigorous research into their daily clinical practice.

It was during this period that Wu decided to permanently ink the Cochrane logo onto his arm, a testament to his commitment to evidence-based healthcare. The logo, displaying the forest plot of an iconic systematic review, serves as a constant reminder for Wu to apply the knowledge and insights gained from Cochrane's resources when making clinical decisions.

Reflecting on the significance of his tattoo, Wu expressed, "My Cochrane tattoo represents my passion for evidence-based healthcare. It serves as a constant reminder to strive for excellence in my clinical practice and to rely on high-quality evidence synthesis rather than individual studies when making clinical decisions. My ultimate aspiration is to work on a review published in the Cochrane Library and make a tangible impact on patient care."

Wu's tattoo is the second known instance of someone getting a Cochrane logo. The first is a parent who chose the Cochrane logo as an expression of gratitude and hope, as their premature baby's life was saved through an intervention supported by Cochrane evidence. These tattoos represent the tangible and lasting impact that Cochrane's work can have on clinicians, individuals, and families.

• Learn about how you can join Cochrane
• #MyCochraneStory - Read other stories about Cochrane Community members

 

Wednesday, June 21, 2023

Specifications: Permanent – Full Time
Salary: £30,000 per annum
Location: (Remote- Flexible) Ideally based in the UK, Germany or Denmark. Candidates from the rest of the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries (1-year fixed-term contracts)
Directorate: Evidence Production and Methods Directorate
Closing date: 02 July 2023

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

“Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world.” Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

As Assistant Quality Assurance Editor within Cochrane’s Editorial Department, you will provide support to the Quality Assurance Editor and Senior Quality Assurance Editor, to help them to assess whether protocols, reviews and updates submitted to Cochrane’s Central Editorial Service have met Cochrane’s methodological standards.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everting we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

• An opportunity to truly impact health globally
• A flexible work environment
• A comprehensive onboarding experiences
• An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

Cochrane has offices with payroll in the UK, Germany and Denmark. Candidates from other countries are employed on consultancy contracts.

How to apply

• For further information on the role and how to apply, please click here
• The deadline to receive your application is 2nd July, 2023.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Read our Recruitment Privacy Statement

Friday, June 16, 2023 Category: Jobs

機能性ディスペプシアに対する中薬（中医学の薬草療法）以外の薬草療法の効果は？ 主要な結果 機能性ディスペプシア患者の症状とウェルビーイング（well-being)の改善に有用な複数の薬草療法を同定した。また、偽治療と比較して、重要な望ましくない事象を伴わないかもしれない。しかしながら、薬草療法と他の治療法の有用性を比較した科学的根拠（エビデンス）はほとんどなかった。 薬草療法の有用性は、機能性ディスペプシアに対する一般的な内科的治療と比較して、相対的な有用性を評価する必要があるかもしれない。機能性ディスペプシアについては、特に一般的な消化器合併症がある人を対象とした、より質の高い試験が必要である。 背景 機能性ディスペプシアとは？ 機能性ディスペプシアは成人において頻繁にみられる健康問題である。胃の痛みや不快感を特徴とする。しかしながら、器質性ディスペプシアとは異なり、これらの症状は胃や腸の潰瘍やその他の病変が原因とはいえない。 機能性ディスペプシアの治療法とは？ この疾患の治療法には薬物療法と非薬物療法があるが、それらにどの程度有用性があるかは不明である。さまざまな薬草（ハーブ）製品が、この症状の治療薬となる可能性があるとしてある程度まで研究が行われている。 わかったこと 本レビューでは、このテーマに関するすべての利用可能な研究を検証し、これらの薬草のどれかが症状やウェルビーイ...

フェノフィブラートは糖尿病網膜症に有効か？ レビューの目的は何か？ 1型糖尿病または2型糖尿病の患者において、フェノフィブラートが、プラセボもしくは経過観察と比較して、糖尿病網膜症の発症を予防するのか、あるいはすでに糖尿病網膜症を発症している場合、その進行を遅らせるのかを明らかにすることが目的である。 要点 - 総じてフェノフィブラートは、プラセボとの比較で、糖尿病網膜症の進行にほとんど差がない可能性が高い（中等度の確実性のエビデンス）。 - 糖尿病網膜症を発症している患者では、フェノフィブラートの服用で、糖尿病網膜症の進行が緩やかになる可能性が高い（中等度の確実性のエビデンス）。 - まれではあるが、フェノフィブラートの服用で副作用が増加した（高度の確実性のエビデンス）。 - さらなる研究が必要である。例えば、1型糖尿病患者を含む研究や、患者が受けた他の治療を考慮した研究、そして重要なのは、糖尿病と共に生きる人々にとって重大なアウトカムを含む研究である。 レビューでは何が検討されたのか？ 糖尿病網膜症とは、目の奥の血管に障害が起きて生じる疾患で、世界的に失明の主な原因であり、社会への負担となっている。視力を守るためには、糖尿病網膜症の発症を予防し、発症した場合には進行を遅らせたり、防いだりしなければならない。このレビューでは、フェノフィブラートがこの目的に有効なのか、プラセボや...

Monday, June 12, 2023

Monday, June 12, 2023

Friday, June 9, 2023

The official #CochraneLondon merchandise is available for purchase at the Cochrane Store. The items include tote bags, mugs, shirts, and more - allowing you to proudly display your support!

Cochrane UK is hosting the highly anticipated Cochrane Colloquium taking place in London, UK from 4-6 September 2023. With the theme “Forward together for trusted evidence”, the 2023 Cochrane Colloquium is set to be a groundbreaking event with a blend of knowledge sharing, networking opportunities, engaging plenary speakers, and captivating events. 

To mark the Colloquium, you can purchase merchandise to wear at #CochraneLondon and cherish as a meaningful souvenir afterwards. In an effort to prioritize sustainability, Cochrane has opted for a print-on-demand store, ensuring a more eco-friendly approach. Please note that these items will not be available for purchase at the Colloquium itself and must be acquired in advance.

"The Ann Anderson Walk is a cherished social event for the Cochrane Community, where Colloquium attendees explore the host city and donate to next year’s Anne Anderson Award. This year the self-guided walk takes people past some notable landmarks of London while teaching you about the surrounding health history and women's contributions to healthcare in London. I encourage everyone to set aside some time for the walk and make a donation. There is so much to see just steps from the conference centre and I am so excited to see this year's map added to the Anne Anderson designs already available in the store."
 
- Tiffany Duque, 2022 winner of the Anne Anderson Award

"It’s been a long time since our last Cochrane Colloquium. We’re bringing together Cochrane researchers, clinical professionals, early career professionals, patients and carers, policymakers, and anyone interested in evidence synthesis and evidence-based healthcare. We know that everyone in our community is excited for this year’s event. Take a look at our great #CochraneLondon items available to help celebrate. Alongside these are our Cochrane 30th Anniversary items, as we will be celebrating this milestone at the colloquium."

- Catherine Spencer, CEO of Cochrane

"The 2023 Cochrane Colloquium is just around the corner. This year’s Colloquium is a special one; with 5 long years since the last Colloquium, we can now come together again, and celebrate 30 years of Cochrane producing trusted evidence. We hope you find something in the Cochrane store as a memento of this historic event and we look forward to welcoming you to London!”

- Martin Burton, Director of Cochrane UK

 

Get some Cochrane London gear now and show your support for evidence-based healthcare!

• Visit the Cochrane Store

Tuesday, July 11, 2023

医薬品の販売方法を規制する政策が及ぼす影響とは？ 要点 多くの国が、製薬業界による製品の販売方法を規制する政策を導入している。しかし、十分に実施された研究が不足しているため、これらの政策がどのような影響を及ぼすかはわかっていない。 医薬品販売政策とは？ 新薬を開発し、市場に出すには非常にコストがかかる。そのため製薬業界は、自社の医薬品を宣伝し、その使用量を増やすために多くのリソースを費やしている。製薬業界はしばしば、患者や消費者にこれらの薬を使うよう勧め、医療専門家に処方するよう勧める。また、医療保険機関や政府にも自社の医薬品を宣伝している。例えば、広告、営業担当者の訪問、医薬品の無料サンプル、教育啓発プログラムなどである。 このような戦略は、健康状態やその治療薬に関する有益な情報を広めることができるが、害を及ぼすこともある。例えば、患者、医師、組織は、不必要で高価な、時には有害な薬を使用したり処方したりするよう説得される可能性がある。 このような問題から、政府や非政府組織はしばしば薬物の宣伝方法を規制しようとする。たとえば、ある国では、製薬業界が患者や消費者に処方薬を宣伝することが禁じられている。他の国々では、医療専門家に対して医薬品の宣伝を行うことは、医学雑誌など特定の方法でしか認められていない。国によっては、政府や組織が 単独で活動する。他の国では、政府や組織が製薬業界と協...

Cochrane recently participated in the 76th World Health Assembly (WHA), the world’s foremost global health policy event. Held at the UN Headquarters in Geneva, the WHA is the decision-making body for the World Health Organization (WHO), attended by representatives of all Member States, as well as NGOs and funding organisations. It is thus a key forum to advocate for evidence-informed health policies.

This year’s event marked the 75th anniversary of WHO’s founding and the agenda was packed with issues to address. Among these was an agreement for Member States to increase contributions to WHO’s budget, health emergency preparedness and response, as well as further discussion of the resolution to strengthen clinical trials passed last year.

WHA76 also marked the historic passing of the first ever resolution on strengthening rehabilitation in health systems. To commemorate the occasion, Cochrane Rehabilitation participated in a side event organised with NGOs and professional associations working in the field of rehabilitation, and sponsored by five Member States. Prof Stefano Negrini, Director of Cochrane Rehabilitation, represented Cochrane and spoke on the panel about the importance of using the best possible evidence for rehabilitation. He highlighted that around 9% of reviews on the Cochrane Library relate to rehabilitation, and the need for specific study designs.

Cochrane was represented at the WHA by Governing Board Co-Chair, Catherine Marshall; Editor in Chief, Dr Karla Soares-Weiser; CEO, Catherine Spencer; our Advocacy and Partnerships Lead, Emma Thompson. Given the historic focus on rehabilitation at the assembly, we were also joined by Prof Stefano Negrini and Dr Carlotte Kiekens from Cochrane Rehabilitation and Dr Cornelia Barth from Cochrane Switzerland.

In addition to following the assembly and attending side events, the team used the opportunity to meet with several of Cochrane’s partners from different WHO departments and other health-related organisations, as well as Dr Erik von Elm, Director of Cochrane Switzerland.

• Learn more about Cochrane's partnership with WHO
• Visit the Cochrane Rehabilitation website

Wednesday, June 7, 2023

Specifications: Permanent – Full Time Role
Salary:  £60,000 per Annum  
Location: (Remote – Flexible) Candidates anywhere from the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries.
Directorate: DEV
Closing date: 25 June 2023
 
Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

To lead the Membership, Learning & Support department in providing strategically-focussed services, providing intelligent pathways for people to get involved through membership, communicating and engaging with them in innovative ways to strengthen and develop their relationship with Cochrane, shaping and offering high quality learning experiences, and supporting people with their enquiries.   

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everting we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.  

You can expect: 

• An opportunity to truly impact health globally  
• A flexible work environment  
• A comprehensive onboarding experiences
• An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here 
• The deadline to receive your application is 25 June 2023.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Read our Recruitment Privacy Statement

Monday, June 5, 2023 Category: Jobs

Specifications: Permanent – Part Time (2 days a Week)
Salary:  £40,000 per annum  (pro rata)
Location: Remote – Flexible
Directorate: DEV
Closing date: 21 June 2023
 
Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

As a new role within the Communications team, the Creative Content Producer will work with colleagues across the organisation to bring our work to life and ensure our branding and visual identity are applied consistently. We’re looking for a self-starter who will be able to take ideas from concept through to final design, working flexibly with colleagues across the organisation.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everting we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.  

You can expect: 

• An opportunity to truly impact health globally  
• A flexible work environment  
• A comprehensive onboarding experiences
• An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

Cochrane has offices with payroll in the UK, Germany and Denmark. Candidates from other countries are employed on consultancy contracts. If you would like more details on how this works, please contact hrenquiries@cochrane.org

How to apply

• For further information on the role and how to apply, please click here
• The deadline to receive your application is 21 June 2023.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Read our Recruitment Privacy Statement

Monday, June 5, 2023 Category: Jobs

がん性疼痛に対する大麻由来の医薬品 大麻に基づく医薬品は成人のがん性疼痛に効くのか？ 要点 大麻由来の医薬品（CbM）は、モルヒネ様医薬品に反応しないがん性疼痛を緩和しなかった。 分析された研究では、世界保健機関（WHO）のがん性疼痛に対する鎮痛薬ラダーにおけるこれらの薬剤の位置づけを示すことはできなかった。 がんにおけるCbMの臨床試験は、これまでに実施されたものよりもはるかに優れたデザインにする必要がある。 がんにおける痛みとその治療 がんに罹った人の2、3人に1人は、中等度または重度の痛みを経験する。痛みはがんの進行とともに強くなる傾向がある。 WHOは、がんによる中等度から重度の痛みに対してモルヒネ様鎮痛薬の服用を推奨しているが、がんの痛みを持つ6人から10人に1人は、モルヒネ様鎮痛薬では十分な鎮痛効果が得られないという。大麻植物をベースにしたいくつかの製品が、がん性疼痛の治療薬として提案されている。これらの製品には、吸入または経口摂取されるハーブ大麻や、植物から得られた、あるいは合成的に作られた大麻の有効成分を含むさまざまなオイル、スプレー、錠剤が含まれる。がん性疼痛のある人の中には、CbMが有効であると報告している人もおり、メディアでもしばしば取り上げられている。 調べたかったこと CbMが、がんと共に生きる人々のがんの痛みを和らげるかどうか。 CbMが何らかの好まし...